Investor Presentaiton
Current COVID-19 status
R&D investor presentation
5
Novo Nordisk status across the value chain
Gradual 'return to normal' across regions
Production
All manufacturing sites operating
Medicines available to patients worldwide
R&D
Commercial
•
•
•
•
Continuation of on-going clinical trials
Trial recruitment negatively impacted, but
gradually improving
Initiation of some new trials
Majority of Novo Nordisk medicines used for
chronic treatment
Fewer patients initiating (new) treatment
Increased Rx duration and stocking resulting in
favourable timing effect - but gradual reversal
expected
F2F: face-to-face; EMEA: Europe, Middle East and Africa; Row: Rest of World
International Operations
North America Operations
•
China approaching pre COVID-19
EMEA and ROW cautiously opening up
~50% of affiliates with some F2F interaction
with doctors
US status varies greatly per state
~70% of sales force partially back in the field
Canada cautiously opening up
novo nordiskView entire presentation